ERS Respiratory Channel

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

Abstract

Introduction: In patients with cystic fibrosis (CF) who carry at least one F508del mutation, treatment with elexacaftor/tezacaftor/ivacaftor (ETI) significantly improves lung function, body mass index and quality of life; however, impacts on body composition have not been well studied.

Aim: Our aim was to investigate the efficacy of ETI on body composition in CF patients with pre-existing advanced lung disease.

Methods: We performed a single-centre, retrospective, observational analysis of the effect of ETI on body composition in CF patients with advanced lung disease (FEV1<40%) who were on triple therapy for at least 6 months.

Results: 11 CF patients (6F, 5M) with FEV1<40% before ETI were included. Differences in BMI and body composition (BMI, FFM, FFMI and Phase angle) before and after at least six months of triple therapy were statistically significant (% change in mean; Wilcoxon p-values reported): BMI 12.2%, FFM 6.3%, FFMI 5.4%, Phase angle 7.23% (p ??.001).

Conclusions: In this study, initiation of ETI in CF patients with pre-existing advanced lung disease was associated with statistically significant improvement in BMI and BIA after at least six months of therapy.

Abstract

#{title}